Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiometabolic and Hepatic Disease Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PCSK7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PCSK7 ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PCSK7 Products |
| Gene Delivery | PCSK7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PCSK7 Products |
| Benchmark Ab | Anti-PCSK7 Recombinant Antibody Positive control for assay validation. |
View PCSK7 Products |
| Validator | PCSK7 siRNA Set For knockdown verification. |
View PCSK7 Products |
| Related Target A | PCSK9 Synergistic lipid metabolism regulation pathway. |
View PCSK9 Products |
| Related Target B | FURIN Essential proprotein convertase; crucial off-target safety filter. |
View FURIN Products |
| Related Target C | TFRC Transferrin receptor; key substrate and iron metabolism partner. |
View TFRC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Off-target cross-reactivity with Furin/PCSK9 | High-purity recombinant PCSK9 and Furin proteins available for counter-screening |
| Conformation-sensitive antibody screening | HEK293-expressed PCSK7 with native glycosylation and folding |
| Lack of validated positive controls | Recombinant benchmark antibodies sequence-verified for assay calibration |
| Assay noise from cell transfection variability | Lentiviral vectors for stable, high-expression cell line generation |
Live PCSK7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PCSK7 therapeutics is intensifying, with major players shifting focus from traditional mAbs to RNA-targeted therapies and small-molecule inhibitors. As first-generation therapies for lipid disorders reach maturity, the next wave of R&&D is targeting PCSK7 for its unique role in non-alcoholic fatty liver disease (NAFLD/NASH), liver fibrosis, and iron overload disorders. Developing highly selective agents that do not cross-react with other proprotein convertases is the primary hurdle in bringing these candidates to clinical success.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| siRNA / RNAi | Alnylam Pharmaceuticals, Arrowhead | NASH, Hepatic Steatosis | Target knockdown validation (Need high-specificity siRNA and qPCR controls) |
| Monoclonal Antibody | Academic institutions, Biotech startups | Hypercholesterolemia, Iron Overload | Epitope mapping & binding affinity (Need HEK293-expressed native PCSK7 ECD) |
| Small Molecule | Pfizer, Merck | Metabolic Syndrome, Cancer | Enzymatic selectivity assays (Need active recombinant PCSK7 vs Furin panel) |